Birmingham Haematologist - Priory Hospital
The Harborne Hospital
The Priory Hospital
Haematology Department
Haematology Department

Dr Prem Mahendra is the leading private consultant haemato-oncologist in the West Midlands. For more than 25 years she has been providing an unparalleled, empathetic and efficient service for patients with blood cancer, and is passionate about delivering outstanding care.  All private patients are seen at the Priory Hospital, Edgbaston, Birmingham.  From January 2024 patients can also be seen at the new Harborne Hospital, Edgbaston, Birmingham.

She is an NHS consultant at the Queen Elizabeth Hospital, Birmingham.

Areas of expertise are care of patients with:

  • Non-Hodgkin lymphoma
  • Hodgkin lymphoma
  • Myeloma
  • Acute myeloid and lymphoblastic leukaemia
  • Chronic lymphocytic and myeloid leukaemia
  • Myelodysplasia
  • Myeloproliferative disorder
  • Waldenstroms macroglobulinaemia

And those undergoing:

  • Autologous stem cell transplantation
  • Allogeneic stem cell transplantation.
  • CAR-T (chimeric antigen receptor-T-cell therapy)


Latest News


Updates from American Society of Hematology Meeting 2023

Myeloma – the phase 3 PERSEUS trial from the European Myeloma Network randomised approximately 700 newly diagnosed patients with myeloma to treatment with dartumumab, velcade...
mantle cell lymphoma

Update on mantle cell lymphoma 15 October 2023

For older non-transplant eligible patients’ initial treatment options are VR-CAP (bortezomib, rituximab, cyclophosphamide, adriamycin and prednisolone based on the LYM 3002 phase 3 trial of...
Priory Hospital Treatment

Priory Hospital treats first patient with Teclistamab a bispecific antibody treatment for myeloma.

Bispecific T-cell engagers are a new and innovative treatment for myeloma. Two bispecific antibodies Teclistamab and Talquetamab have been approved by the EMA for the...

Myeloma Treatment – “remarkably effective” in the treatment of myeloma

Whilst access to CAR-T therapy is only available by entry into clinical trials in the UK currently, recent results of ciltacabtagene autoleucel (also known as...
hodgkins lymphoma

Hodgkin Lymphoma? A new standard of care for advanced stage patients

For decades the standard treatment for patients with advanced Hodgkin lymphoma has been combination chemotherapy with either ABVD or escalated BEACOPP. Approximately 5 years ago...
diffuse-large B-cell lymphoma

Exciting new treatment for diffuse-large B-cell lymphoma approved by the European Medicines Agency (EMA).

In July 2023 the EMA approved Glofitamab, one of the most potent single drugs available for the treatment of relapsed/refractory DLBCL. Glofitamab is a CD20xCD3...
Diffuse large B-cell lymphoma

Diffuse-large B-cell lymphoma – Ground breaking new treatment available for relapsed/refractory patients

For over 30-years autologous stem cell transplantation has been the standard of care for patients with relapsed diffuse-large B-cell lymphoma (DLBCL). The international Zuma-7 trial...

AXA Health Insurance
Healix Health Insurance
Aviva Health Insurance
Cigna Insurance
Vitality Heath Insurance